Solutions for Change

DMK Pharmaceuticals is a clinical stage neuro-biotechnology company committed to patients. Our commercial and development products aim to address areas of significant unmet medical need.

ZIMHI technology video

ZIMHI Technology – watch our video that explains how it works

Scientist working in a lab

About Us

DMK Pharmaceuticals is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas.

Commercially approved products:

  • ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue
  • SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

The following molecules are in development:.

  • DPI-125 for the treatment of Opioid Use Disorder (OUD).
  • DPI-221 for the treatment of benign prostatic hyperplasia (BPH).
  • DPI-289 for the treatment of Parkinson’s disease.
Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.